ID   ZYXY-T1
AC   CVCL_B6YT
DR   CCRID; 4201PAT-CCTCC01826
DR   Wikidata; Q112041952
RX   Patent=CN112877290B;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC 202143.
CC   Population: Chinese.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): Patent=CN112877290B
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D12S391: 19,21
ST   D13S317: 9
ST   D16S539: 8,11
ST   D18S51: 14,19
ST   D19S433: 13,13.2
ST   D1S1656: 17.3,18.3
ST   D21S11: 30,31
ST   D2S1338: 23
ST   D3S1358: 14,17
ST   D5S818: 10,13
ST   D6S1043: 13
ST   D7S820: 12,13
ST   D8S1179: 13,14
ST   FGA: 23,24
ST   Penta D: 10,11
ST   Penta E: 15,19
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 14,15
DI   NCIt; C130043; Early T acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
CA   Cancer cell line
DT   Created: 17-03-22; Last updated: 29-06-23; Version: 4
//
RX   Patent=CN112877290B;
RA   Jin J., Li F.-L., Wang H.-F., Zhu H.-H., Huang X., Zhang Y., Hu C.;
RT   "Human T lymphoblastic leukemia/lymphoma cell line and application
RT   thereof.";
RL   Patent number CN112877290B, 30-Nov-2021.
//